Indoramin as second step therapy in the management of benign essential hypertension

A. S. Montenero, M. Mazzari, G. Schiavoni, U. Manzoli, S. Gherardi

Research output: Contribution to journalArticle

Abstract

An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker. After a 1-week washout period, patients started treatment with 25 mg indoramin twice daily plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily). Indoramin dosage was subsequently adjusted in 25 mg steps (to maximum 150 mg daily), if necessary, at follow-up control visits every 14 days. Analysis of the results from the 22 patients who completed the 75-day study period showed that there were progressive, statistically significant reductions in systolic and diastolic blood pressure (supine and erect) to clinically acceptable levels. Heart rate also decreased significantly and this was more evident in the 7 patients treated with the combination of indoramin, thiazide plus beta-blocker. No patient had orthostatic hypotension and few side-effects were reported, although 7 patients withdrew for this reason.

Original languageEnglish
Pages (from-to)417-421
Number of pages5
JournalPharmatherapeutica
Volume3
Issue number6
Publication statusPublished - 1983

Fingerprint

Indoramin
Thiazides
Therapeutics
Blood Pressure
Orthostatic Hypotension
Hydrochlorothiazide
Propranolol
Essential Hypertension
Heart Rate
Hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Montenero, A. S., Mazzari, M., Schiavoni, G., Manzoli, U., & Gherardi, S. (1983). Indoramin as second step therapy in the management of benign essential hypertension. Pharmatherapeutica, 3(6), 417-421.

Indoramin as second step therapy in the management of benign essential hypertension. / Montenero, A. S.; Mazzari, M.; Schiavoni, G.; Manzoli, U.; Gherardi, S.

In: Pharmatherapeutica, Vol. 3, No. 6, 1983, p. 417-421.

Research output: Contribution to journalArticle

Montenero, AS, Mazzari, M, Schiavoni, G, Manzoli, U & Gherardi, S 1983, 'Indoramin as second step therapy in the management of benign essential hypertension', Pharmatherapeutica, vol. 3, no. 6, pp. 417-421.
Montenero AS, Mazzari M, Schiavoni G, Manzoli U, Gherardi S. Indoramin as second step therapy in the management of benign essential hypertension. Pharmatherapeutica. 1983;3(6):417-421.
Montenero, A. S. ; Mazzari, M. ; Schiavoni, G. ; Manzoli, U. ; Gherardi, S. / Indoramin as second step therapy in the management of benign essential hypertension. In: Pharmatherapeutica. 1983 ; Vol. 3, No. 6. pp. 417-421.
@article{0f671bfbf9b64d00a3f80ba1cef52e11,
title = "Indoramin as second step therapy in the management of benign essential hypertension",
abstract = "An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker. After a 1-week washout period, patients started treatment with 25 mg indoramin twice daily plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily). Indoramin dosage was subsequently adjusted in 25 mg steps (to maximum 150 mg daily), if necessary, at follow-up control visits every 14 days. Analysis of the results from the 22 patients who completed the 75-day study period showed that there were progressive, statistically significant reductions in systolic and diastolic blood pressure (supine and erect) to clinically acceptable levels. Heart rate also decreased significantly and this was more evident in the 7 patients treated with the combination of indoramin, thiazide plus beta-blocker. No patient had orthostatic hypotension and few side-effects were reported, although 7 patients withdrew for this reason.",
author = "Montenero, {A. S.} and M. Mazzari and G. Schiavoni and U. Manzoli and S. Gherardi",
year = "1983",
language = "English",
volume = "3",
pages = "417--421",
journal = "Pharmatherapeutica",
issn = "0308-051X",
number = "6",

}

TY - JOUR

T1 - Indoramin as second step therapy in the management of benign essential hypertension

AU - Montenero, A. S.

AU - Mazzari, M.

AU - Schiavoni, G.

AU - Manzoli, U.

AU - Gherardi, S.

PY - 1983

Y1 - 1983

N2 - An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker. After a 1-week washout period, patients started treatment with 25 mg indoramin twice daily plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily). Indoramin dosage was subsequently adjusted in 25 mg steps (to maximum 150 mg daily), if necessary, at follow-up control visits every 14 days. Analysis of the results from the 22 patients who completed the 75-day study period showed that there were progressive, statistically significant reductions in systolic and diastolic blood pressure (supine and erect) to clinically acceptable levels. Heart rate also decreased significantly and this was more evident in the 7 patients treated with the combination of indoramin, thiazide plus beta-blocker. No patient had orthostatic hypotension and few side-effects were reported, although 7 patients withdrew for this reason.

AB - An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker. After a 1-week washout period, patients started treatment with 25 mg indoramin twice daily plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily). Indoramin dosage was subsequently adjusted in 25 mg steps (to maximum 150 mg daily), if necessary, at follow-up control visits every 14 days. Analysis of the results from the 22 patients who completed the 75-day study period showed that there were progressive, statistically significant reductions in systolic and diastolic blood pressure (supine and erect) to clinically acceptable levels. Heart rate also decreased significantly and this was more evident in the 7 patients treated with the combination of indoramin, thiazide plus beta-blocker. No patient had orthostatic hypotension and few side-effects were reported, although 7 patients withdrew for this reason.

UR - http://www.scopus.com/inward/record.url?scp=0020555511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020555511&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 417

EP - 421

JO - Pharmatherapeutica

JF - Pharmatherapeutica

SN - 0308-051X

IS - 6

ER -